Winton Group’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
Other funds holding AVDL
GJL
WAM
TAL
VC
Winton Group's AVDL Position: Q4 2025 in Review
Winton Group sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 47,635 shares — an estimated $727K sold.
Winton Group first reported a position in AVDL in Q3 2025 and held it in 1 quarter. The position peaked at $727K in Q3 2025. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.
- Winton Group reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Winton Group sold 47,635 Avadel Pharmaceuticals shares in Q4 2025, an estimated $727K.
- Winton Group first reported a position in Avadel Pharmaceuticals in Q3 2025 and held it in 1 quarter.
- Winton Group's Avadel Pharmaceuticals position peaked at $727K in Q3 2025.
- 207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.
Based on Winton Group's 13F filing for Q4 2025, filed 11 Feb 2026.